The firm said it will offer 25 million units consisting of common stock and common warrants at $.40 per unit.
The firm said that a number of hospitals and labs are expected to evaluate the panel, presenting it with about a $2.0 million annual revenue opportunity.
The company's Acuitas test provides information on the presence of 10 MDRO resistance genes in a single sample.
The assay is based on real-time reverse transcriptase PCR that will identify Zika in human serum or urine.
The firm's real-time PCR-based GeneStat system was developed leveraging IP licensed exclusively from the Translational Genomics Research Institute.
The test, which is currently for research use only, uses fluorescent multiplex PCR to co-amplify seven markers for analysis of the MSI-high phenotype.
The test, which simultaneously detects MRSA and Staphylococcus aureus, is designed to run on the company's Liat PCR point-of-care platform.
Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.
With CE marking for the gram-positive and gram-negative panels, the firm has achieved the designation for its family of three ePlex bloodstream infection assays.
The company launched the MassArray System with Chip Prep Module in Europe for general IVD use, targeting hospitals and laboratories.
The firm said that its Panther Fusion system expands molecular testing capabilities, and increases productivity and flexibility for labs.
The tests were previously available in New York state on a patient-by-patient basis through a non-permitted laboratory testing program.
The firm's real-time PCR assay for rapid detection and differentiation of novovirus genogroup I and II runs on the Aries sample-to-answer system.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
The test, designed to simultaneously detect diarrhea-causing enteric viruses using DNA extracted from a stool sample, includes norovirus GI, norovirus GII, and others.
The Aptima HSV 1 & 2 nucleic acid amplification test qualitatively detects and differentiates between HSV-1 and HSV-2 on the automated Panther system.
The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
The tests are all based on the company's dual-capture, dual-sequencing platform method.
The lung cancer test, which can detect 51 EGFR mutations, is the fifth assay for cancer that the Belgian molecular diagnostics firm has CE marked.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.